Search Result

Results for "

low-density lipoprotein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LDLR (7) Acyltransferase (1) Akt (2) AMPK (1) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (11) Autophagy (14) Bacterial (5) Biochemical Assay Reagents (2) Calcium Channel (1) CETP (2) COX (2) Cytochrome P450 (1) Endogenous Metabolite (7) ERK (3) Ferroptosis (3) FXR (2) Glucosidase (1) HMG-CoA Reductase (HMGCR) (18) Interleukin Related (1) Isotope-Labeled Compounds (4) Keap1-Nrf2 (2) Lipoxygenase (1) LXR (1) Mitophagy (6) NF-κB (2) NO Synthase (1) NOD-like Receptor (NLR) (1) p38 MAPK (3) PCSK9 (14) PKA (2) Potassium Channel (8) PPAR (3) RAR/RXR (1) Reactive Oxygen Species (3) ROR (2) Thyroid Hormone Receptor (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (30) Endocrinology (2) Inflammation/Immunology (10) Metabolic Disease (50) Neurological Disease (4)
Oligonucleotides:	Fillers (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: LDLR LOX-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-NP013

*Oxidized low density* lipoprotein (mouse)** Mouse ox-LDL	LDLR	Cardiovascular Disease
Oxidized low density lipoprotein (mouse) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration .

HY-113288

Campestanol	Others	Metabolic Disease
Campestanol is a phytosterol that can be found in plant food. Campestanol lowers serum cholesterol and low-density lipoprotein. Campestanol can be used for the research of metabolic disorders .

HY-109523

Cerivastatin sodium	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-145001

20-HC-Me-Pyrrolidine	Others	Metabolic Disease
20-HC-Me-Pyrrolidine is a potent Aster protein inhibitor with IC₅₀s of 0.11 μM, 0.06 μM, and 0.71 μM for Aster-A, Aster-B, and Aster-C, respectively. 20-HC-Me-Pyrrolidine blocks the ability of Asters to bind and transfer cholesterol. 20-HC-Me-Pyrrolidine also inhibits the movement of low-density lipoprotein (LDL) cholesterol to the endoplasmic reticulum (ER) .

HY-NP135

*Oxidized low density* lipoprotein (Human)** Human ox-LDL	NO Synthase NOD-like Receptor (NLR)	Metabolic Disease Inflammation/Immunology
Oxidized low density lipoprotein (Human) (Human ox-LDL) is involved in atherogenesis. Oxidized low density lipoprotein (Human) induces endothelial dysfunction via cytoplasmic adapter protein TRAF3IP2. Oxidized low density lipoprotein (Human) can stimulate the activation of endothelial cells and the production of adhesion molecules, and inhibits eNOS activity and NO production. Oxidized low density lipoprotein (Human) can activate NLRP3 inflammasome in macrophages .

HY-115914

Lipid-lowering agent-1	Others	Others
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .

HY-153451

PCSK9-IN-15	PCSK9	Metabolic Disease
PCSK9-IN-15 (compound 5) is a potent inhibitor of proprotein convertase subtilisin/kexin 9 (PCSK9, K_D <200 nM). PCSK9 is involved in cholesterol metabolism and regulates levels of low-density lipoprotein cholesterol (LDL-C) in the blood. PCSK9- in -15 can be used to study cholesterol-lowering and dyslipidemia .

HY-129458

Cerivastatin	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-148626

CVI-LM001	PCSK9	Metabolic Disease
CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .

HY-109523S

Cerivastatin-d3 sodium	Ferroptosis HMG-CoA Reductase (HMGCR) Isotope-Labeled Compounds	Cardiovascular Disease Cancer
Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-120651

LDL-IN-2	LDLR	Metabolic Disease
LDL-IN-2 (compound 3) is an antioxidant against copper mediated low-density lipoproteins (LDL) oxidation .

HY-17504B

Rosuvastatin Sodium 10+ Cited Publications ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial	Cardiovascular Disease Metabolic Disease
Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-123260

S12340	LDLR	Cardiovascular Disease
S12340 is a a inhibitor of the oxidative modification of low-density lipoprotein and shows protective effect on cardiac cells exposed to oxidative stress .

HY-147279

Milpocitide	LDLR	Others
Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .

HY-17504

Rosuvastatin Calcium 10+ Cited Publications Rosuvastatin hemicalcium; ZD 4522 Calcium	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504BS2

Rosuvastatin-13C,d3 sodium ZD 4522-₁₃C,d₃ sodium; X-Plended-₁₃C,d₃ sodium; Crestor-₁₃C,d₃ sodium	Autophagy Bacterial HMG-CoA Reductase (HMGCR) Potassium Channel Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease
Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-126933

Palmitoyl rhizoxin RS-1541	Others	Cancer
Palmitoyl rhizoxin (RS-1541), a 13-0-palmitoyl derivative of Rhizoxin, is a potent antineoplastic agent with anti-tumour activity. Palmitoyl rhizoxin binds to the *lipoproteins* and the low-density lipoprotein (LDL) receptors in M5076 sarcoma .

HY-161940

PCSK9-IN-30	PCSK9	Cardiovascular Disease
PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC₅₀ = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases .

HY-17504A

Rosuvastatin ZD 4522	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-129982

SC-435	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
SC-435 is an apical sodium-dependent Bile acid (BA) transporter inhibitor. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations .

HY-W510159

5-O-Methylembelin	PCSK9	Cardiovascular Disease
5-O-Methylembelin is a natural isocoumarin that inhibits PCSK9, *inducible degrader of the low-density* lipoprotein receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2)** mRNA expression .

HY-W134326

Polydextrose	Biochemical Assay Reagents	Metabolic Disease Cancer
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .

HY-N13235

Garlic Extract	Others	Cardiovascular Disease
Garlic Extract is a garlic extract, and its components include: Allicin. Garlic Extract is beneficial to cardiovascular disease and has the potential to reduce the risk of cardiovascular disease. Garlic Extract can effectively reduce total cholesterol, low-density lipoprotein levels and improve high-density lipoprotein levels. .

HY-148758

PCSK9-IN-13	PCSK9	Metabolic Disease
PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC₅₀ of 537 nM .

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized **low-density lipoproteins (oxLDL**). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

HY-132303

MK-8262	CETP	Cardiovascular Disease Metabolic Disease
MK-8262 is an orally active and potent *cholesteryl ester transfer protein* (CETP) inhibitor with an IC₅₀** of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-density lipoprotein (HDL) and low-density lipoprotein (LDL) research .

HY-109567

Gemcabene PD-72953	Others	Metabolic Disease Inflammation/Immunology
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-113269

alpha-CEHC	Others	Others
alpha-CEHC is a water-soluble metabolite of alpha-tocopherol (α-TOH) with potential antioxidant activity. alpha-CEHC slightly inhibits macrophage-induced low-density lipoprotein (LDL) oxidation, and its inhibitory potency is concentration-dependent .

HY-109567A

Gemcabene calcium PD-72953 calcium	Others	Metabolic Disease Inflammation/Immunology
Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-161942

PCSK9-IN-31	PCSK9	Metabolic Disease
PCSK9-IN-31 (Compound WX002) is an orally active PCSK9 inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats .

HY-128334

PCSK9 modulator-2	PCSK9	Metabolic Disease
PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC₅₀ value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia .

HY-146084

PCSK9 modulator-3	PCSK9	Metabolic Disease
PCSK9 modulator-3 (Compound 13) is a potent modulator of PCSK9 with an EC₅₀ value of 2.46 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-3 has the potential for the research of hyperlipidemia .

HY-146085

PCSK9 modulator-4	PCSK9	Metabolic Disease
PCSK9 modulator-4 (Compound 21) is a potent modulator of PCSK9 with an EC₅₀ value of 0.15 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-4 has the potential for the research of hyperlipidemia .

HY-16274

Lapaquistat acetate TAK-475	Others	Metabolic Disease
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .

HY-N0120

(E/Z)-Polydatin (E/Z)-Piceid	Others	Inflammation/Immunology
(E/Z)-Polydatin ((E/Z)-Piceid) is a monocrystalline compound originally isolated from the root and rhizome of Polygonum cuspidatum. (E/Z)-Polydatin has anti-platelet aggregation, anti-oxidative action of low-density lipoprotein (LDL), cardioprotective activity, anti-inflammatory and immune-regulating functions .

HY-10473

Eprotirome KB2115	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .

HY-130245

PCSK9 degrader 1	PCSK9	Metabolic Disease
PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a K_i of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor .

HY-N1881

4',5-Dihydroxyflavone	Lipoxygenase Glucosidase	Others
4',5-Dihydroxyflavone is a soybean LOX-1 and yeast α-Glucosidase inhibitor, with an K_i of 102.6 μM for soybean LOX-1 and an IC₅₀ of 66 μM for yeast α-glucosidase. LOX-1 isshort for Lectin-like oxidized low-density lipoprotein receptor-1.

HY-N10638

N-Acetyldopamine dimer-2	Reactive Oxygen Species NF-κB	Inflammation/Immunology
N-Acetyldopamine dimer-2 (compound 2) is a N-acetyldopamine dimer that can be isolated from the yellow powder form Periostracum Cicadae with antioxidant and anti-inflammatory activities. N-Acetyldopamine dimer-2 inhibits oxidized low-density lipoprotein (LDL) oxidation, ROS generation, NO production, and NF-κB activity .

HY-113046

5-Methyltetrahydrofolic acid 5 Publications Verification 5-Methyl THF; 5-MTHF	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .

HY-B0144AS1

Pitavastatin-d5 sodium NK-104-d₅ sodium	Apoptosis HMG-CoA Reductase (HMGCR) Mitophagy Autophagy	Metabolic Disease Cancer
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Recaticimab can bind to PCSK9 and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia .

HY-116175

BIBB 515	Others	Metabolic Disease
BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED₅₀ values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL) .

HY-156081

Nrf2 activator-9	Keap1-Nrf2 Apoptosis	Metabolic Disease
Nrf2 activator-9 (compound D-36) is an Nrf2 activator that inhibits oxidized low-density lipoprotein (oxLDL) and high glucose (HG)-induced apoptosis in HUVEC cells. Nrf2 activator-9 inhibits oxLDL and HG-induced vascular endothelial cell (VEC) injury and can effectively prevent and treat atherosclerosis .

HY-N0483

Phillygenin 2 Publications Verification Phillygenol; Epipinoresinol methyl ether; (+)-Phillygenin	Reactive Oxygen Species	Others
Phillygenin (Phillygenol) is an active ingredient from Forsythia with many medicinal properties, such as antioxidant, reducing blood lipid, inhibition of low density lipoprotein oxidation.

HY-134154

PAz-PC PAzePC; Azelaoyl PC; 1-Palmitoyl-2-Azelaoyl PC	Endogenous Metabolite	Metabolic Disease
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. Many of these substances were isolated and purified from oxLDL and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. PAz-PC (Azelaoyl PC) is one of the predominant oxLDL species and may be one of the important structural determinants of oxLDL.

HY-10626

T0901317 25+ Cited Publications	LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 is an orally active and highly selective LXR agonist with an EC₅₀ of 20 nM for LXRα . T0901317 activates FXR with an EC₅₀ of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with K_i values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9	Cardiovascular Disease
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

HY-112490

Atorvastatin calcium hydrate Maximum Cited Publications 36 Publications Verification	HMG-CoA Reductase (HMGCR)	Cardiovascular Disease Others
Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.

HY-W041171

3-Chloro-L-tyrosine 3-Chlorotyrosine	Endogenous Metabolite	Others
3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima.

Cat. No.	Product Name	Type

HY-NP013

*Oxidized low density* lipoprotein (mouse)** Mouse ox-LDL	Native Proteins
Oxidized low density lipoprotein (mouse) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration .

HY-W134326

Polydextrose	Biochemical Assay Reagents
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .

HY-139414

Lysophosphatidylcholines 1 Publications Verification	Cell Assay Reagents
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .

HY-126726

KOdiA-PC

Drug Delivery

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

HY-NP012

Low density lipoprotein (human) Human LDL	Native Proteins
Low density lipoprotein (human) is one of the five major groups of lipoprotein that carries cholesterol to various tissues such as the adrenal gland, gonads, muscle, and adipose tissue .

HY-NP135

Oxidized low density lipoprotein (Human)

Human ox-LDL

Native Proteins

Oxidized low density lipoprotein (Human) (Human ox-LDL) is involved in atherogenesis. Oxidized low density lipoprotein (Human) induces endothelial dysfunction via cytoplasmic adapter protein TRAF3IP2. Oxidized low density lipoprotein (Human) can stimulate the activation of endothelial cells and the production of adhesion molecules, and inhibits eNOS activity and NO production. Oxidized low density lipoprotein (Human) can activate NLRP3 inflammasome in macrophages .

Cat. No.	Product Name	Target	Research Area

HY-P4073

ANG1005 GRN1005; Paclitaxel trevatide	Peptides	Cancer
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .

HY-P10502

L57	Peptides	Others
L57 exhibits high affinity to the low-density lipoprotein receptor-related protein 1 (LRP1) with K_i of 45 nM. L57 exhibits blood-brain barrier (BBB) permeability and plasma stability. L57 can be utilized as the carrier for CNS drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized **low-density lipoproteins (oxLDL**). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Recaticimab can bind to PCSK9 and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia .

HY-P9928A

Alirocumab (anti-PCSK9) 1 Publications Verification REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)	PCSK9	Cardiovascular Disease
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W510159

5-O-Methylembelin	Structural Classification Lysimachia vulgarisL. Source classification Coumarins Phenylpropanoids Plants Primulaceae	PCSK9
5-O-Methylembelin is a natural isocoumarin that inhibits PCSK9, *inducible degrader of the low-density* lipoprotein receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2)** mRNA expression .

HY-W134326

Polydextrose	Classification of Application Fields Disease Research Fields Cancer	Biochemical Assay Reagents
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .

HY-N0120

(E/Z)-Polydatin (E/Z)-Piceid	Structural Classification Stilbenes Classification of Application Fields Polygonaceae Reynoutria japonica Houtt. Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	Others
(E/Z)-Polydatin ((E/Z)-Piceid) is a monocrystalline compound originally isolated from the root and rhizome of Polygonum cuspidatum. (E/Z)-Polydatin has anti-platelet aggregation, anti-oxidative action of low-density lipoprotein (LDL), cardioprotective activity, anti-inflammatory and immune-regulating functions .

HY-N1881

4',5-Dihydroxyflavone	Structural Classification Flavonoids Classification of Application Fields Flavones Leguminosae Glycine max (L.) merr Source classification Other Diseases Phenols Polyphenols Plants Disease Research Fields	Lipoxygenase Glucosidase
4',5-Dihydroxyflavone is a soybean LOX-1 and yeast α-Glucosidase inhibitor, with an K_i of 102.6 μM for soybean LOX-1 and an IC₅₀ of 66 μM for yeast α-glucosidase. LOX-1 isshort for Lectin-like oxidized low-density lipoprotein receptor-1.

HY-113046

5-Methyltetrahydrofolic acid 5 Publications Verification 5-Methyl THF; 5-MTHF	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .

HY-N0483

Phillygenin 2 Publications Verification Phillygenol; Epipinoresinol methyl ether; (+)-Phillygenin	Structural Classification Monophenols Classification of Application Fields Oleaceae Source classification Lignans Other Diseases Phenols Phenylpropanoids Plants Forsythia suspensa (Thunb.) Vahl Disease Research Fields	Reactive Oxygen Species
Phillygenin (Phillygenol) is an active ingredient from Forsythia with many medicinal properties, such as antioxidant, reducing blood lipid, inhibition of low density lipoprotein oxidation.

HY-112490

Atorvastatin calcium hydrate Maximum Cited Publications 36 Publications Verification	Cardiovascular Disease Classification of Application Fields Disease Research Fields	HMG-CoA Reductase (HMGCR)
Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.

HY-W041171

3-Chloro-L-tyrosine 3-Chlorotyrosine	Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima.

HY-N2339

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; Cholesterol behenate	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

HY-17504A

Rosuvastatin ZD 4522	Classification of Application Fields Disease Research Fields Cancer	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-N5015

Rosmanol	Structural Classification Brachyclados megalanthus Speg. Classification of Application Fields Labiatae Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	COX
Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.

HY-112540B

Acetoacetic acid sodium 3 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Acetoacetic acid sodium is a metabolite of non-esterified fatty acids, involved in the development of human diabetes. Acetoacetic acid sodium induces oxidative stress to inhibit the assembly of very low density lipoprotein in bovine hepatocytes .

HY-N5015R

Rosmanol (Standard)	Structural Classification Brachyclados megalanthus Speg. Labiatae Source classification Phenols Polyphenols Plants	COX
Rosmanol (Standard) is the analytical standard of Rosmanol. This product is intended for research and analytical applications. Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.

HY-N2118

Bilobetin 1 Publications Verification	Structural Classification Flavonoids Ginkgoaceae Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Biflavones Ginkgo biloba Disease Research Fields	PPAR PKA Akt p38 MAPK ERK
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-N2118R

Bilobetin (Standard)	Structural Classification Flavonoids Ginkgoaceae Source classification Phenols Polyphenols Plants Biflavones Ginkgo biloba	PPAR PKA Akt p38 MAPK ERK
Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

Species:	Human (10) Mouse (2) Rat (2) Cynomolgus (1)
Tag:	His (11) Avi (1) Fc (4)
Source:	HEK293 (15)

Cat. No.	Compare	Product Name	Species	Source

HY-P73272

	LDLR Protein, Mouse (HEK293, His) low-density lipoprotein receptor; LDLR; LDL Receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag. The total length of LDLR Protein, Mouse (HEK293, His) is 769 a.a., with molecular weight of ~98-130 kDa.

HY-P70235

	LDLR Protein, Human (HEK293, His) 2 Publications Verification rHulow-density lipoprotein receptor/LDLR, His; low-density lipoprotein Receptor; LDL Receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293, His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P76477

	LRP-11 Protein, Human (HEK293, His) low-density lipoprotein receptor-related protein 11; LRP-11	Human	HEK293

HY-P77057

	LDLRAD3 Protein, Human (HEK293, Fc) low-density lipoprotein receptor class A domain-containing protein 3; LRAD3	Human	HEK293
	LDLRAD3 protein significantly affects the processing of amyloid precursor protein (APP), possibly reducing soluble APP-α (sAPP-α) and increasing the production of amyloid P3 peptide. Suggested regulation of ITCH and NEDD4 E3 ligases. LDLRAD3 Protein, Human (HEK293, Fc) is the recombinant human-derived LDLRAD3 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P77057A

	LDLRAD3 Protein, Human (HEK293, hFc) low-density lipoprotein receptor class A domain-containing protein 3; LRAD3	Human	HEK293
	LDLRAD3 protein significantly affects the processing of amyloid precursor protein (APP), possibly reducing soluble APP-α (sAPP-α) and increasing the production of amyloid P3 peptide. Suggested regulation of ITCH and NEDD4 E3 ligases. LDLRAD3 Protein, Human (HEK293, hFc) is the recombinant human-derived LDLRAD3, expressed by HEK293 , with C-hFc labeled tag. ,

HY-P76476

	LRP-10 Protein, Human (HEK293, His) low-density lipoprotein receptor-related protein 10; LRP-10; MSTP087; SP220	Human	HEK293
	The LRP-10 protein is a possible receptor that may mediate internalization and/or signaling of lipophilic molecules.It is speculated that LRP-10 can promote the uptake of lipoprotein APOE in the liver and may play a role in lipid metabolism and processes related to lipoprotein transport.LRP-10 Protein, Human (HEK293, His) is the recombinant human-derived LRP-10 protein, expressed by HEK293 , with C-His labeled tag.

HY-P70946

	LRP-12 Protein, Human (HEK293, His) low-density lipoprotein Receptor-Related Protein 12; LRP-12; Suppressor of Tumorigenicity 7 Protein; LRP12; ST7	Human	HEK293
	LRP-12, a probable receptor, potentially facilitates the internalization of lipophilic molecules and signal transduction. It may function as a tumor suppressor and interacts with proteins RACK1, ZFYVE9, and NMRK2. LRP-12 Protein, Human (HEK293, His) is the recombinant human-derived LRP-12 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72392

	LDLR Protein, Human (Biotinylated, HEK293, Avi-His) low-density lipoprotein Receptor; LDL Receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (Biotinylated, HEK293, Avi-His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

HY-P73838

	LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) low-density lipoprotein receptor; LDLR; LDL Receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag and A23V, C27G mutation.

HY-P76475

	LRP-10 Protein, Human (HEK293, Fc) low-density lipoprotein receptor-related protein 10; LRP-10; MSTP087; SP220	Human	HEK293
	The LRP-10 protein is a possible receptor that may mediate internalization and/or signaling of lipophilic molecules.It is speculated that LRP-10 can promote the uptake of lipoprotein APOE in the liver and may play a role in lipid metabolism and processes related to lipoprotein transport.LRP-10 Protein, Human (HEK293, Fc) is the recombinant human-derived LRP-10 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P76125

	VLDLR Protein, Human (HEK293, His) Very low-density lipoprotein receptor; VLDL-R	Human	HEK293
	VLDLR protein, a versatile receptor, mediates energy metabolism by binding and transporting VLDL into cells. It interacts with Reelin/RELN, APOE-containing ligands, and clusterin/CLU. Inactive VLDLR forms oligomers with LRP8, but upon ligand binding, it rearranges to transmit the extracellular RELN signal via DAB1 phosphorylation, regulating neuron positioning. VLDLR also acts as a stop signal for migrating neurons and serves as a receptor for Semliki Forest virus during microbial infection. VLDLR Protein, Human (HEK293, His) is the recombinant human-derived VLDLR protein, expressed by HEK293, with C-His labeled tag. The total length of VLDLR Protein, Human (HEK293, His) is 770 a.a., with molecular weight (glycosylation form) of 110-130 kDa.

HY-P73835

	LOX-1/OLR1 Protein, Rat (HEK293, His) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Rat	HEK293
	The LOX-1/OLR1 protein plays an important role as a receptor that recognizes, internalizes, and degrades oxidatively modified low-density lipoprotein (oxLDL), a marker of atherosclerosis, in vascular endothelial cells. OxLDL induces endothelial dysfunction, triggering pro-inflammatory responses, oxidative conditions, and apoptosis. LOX-1/OLR1 Protein, Rat (HEK293, His) is the recombinant rat-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-His labeled tag. The total length of LOX-1/OLR1 Protein, Rat (HEK293, His) is 305 a.a., with molecular weight of 43-47 kDa.

HY-P73836

	LOX-1/OLR1 Protein, Rat (HEK293, Fc) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Rat	HEK293
	The LOX-1/OLR1 protein plays an important role as a receptor that recognizes, internalizes, and degrades oxidatively modified low-density lipoprotein (oxLDL), a marker of atherosclerosis, in vascular endothelial cells. OxLDL induces endothelial dysfunction, triggering pro-inflammatory responses, oxidative conditions, and apoptosis. LOX-1/OLR1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-hFc labeled tag. The total length of LOX-1/OLR1 Protein, Rat (HEK293, Fc) is 305 a.a., with molecular weight of ~66 & 35 kDa, respectively.

HY-P76474

	LOX-1/OLR1 Protein, Cynomolgus (HEK293, His) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Cynomolgus	HEK293
	OLR1 is a type II membrane glycoprotein belonging to C-type lectin family with a short N-terminal cytoplasmic tail and a long C-terminal extracellular domain. OLR1 binds ox-LDL, delipidated, and solubilized ox-LDL. LOX-1/OLR1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-His labeled tag. The total length of LOX-1/OLR1 Protein, Cynomolgus (HEK293, His) is 213 a.a., with molecular weight of ~37 KDa.

HY-P71180

	OLR1 Protein, Human (HEK293, His) Oxidized low-density lipoprotein Receptor 1; Ox-LDL Receptor 1; C-Type Lectin Domain Family 8 Member A; Lectin-Like Oxidized LDL Receptor 1; LOX-1; Lectin-Like oxLDL Receptor 1; hLOX-1; Lectin-Type Oxidized LDL Receptor 1; OLR1; CLEC8A; LOX1	Human	HEK293
	The OLR1 protein is a receptor on vascular endothelial cells that plays a key role in the recognition, internalization, and degradation of oxidatively modified low-density lipoprotein (oxLDL). As a marker of atherosclerosis, oxLDL induces activation of vascular endothelial cells, leading to proinflammatory responses, oxidative conditions, and apoptosis. OLR1 Protein, Human (HEK293, His) is the recombinant human-derived OLR1 protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0144AS1

Pitavastatin-d5 sodium
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-109523S

Cerivastatin-d3 sodium

Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-17504BS2

Rosuvastatin-13C,d3 sodium

Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-B0144S

Pitavastatin-d4 hemicalcium

Pitavastatin-d₄ (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

HY-W041171S

3-Chloro-L-tyrosine-13C6
3-Chloro-L-tyrosine- ¹³C₆ is the ¹³C labeled 3-Chloro-L-tyrosine[1]. 3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima[2].

HY-17504AS

Rosuvastatin-d3
Rosuvastatin-d₃ is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81166

	ox-LDL Antibody ox-LDL: LDL (Copper oxidized); Cu2SO4 oxidized low density lipoprotein; oxidized low density lipoprotein; low density lipoprotein; MDA oxidized LDL; MDA oxidized low density lipoprotein. 氧化型低密度脂蛋白；	ELISA, IHC-P, IHC-F, FC, ICC/IF	Human
	ox-LDL Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-ox-LDL polyclonal antibody. ox-LDL Antibody can be used for: ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, background without labeling.

HY-P82383

	ApoER2 Antibody (YA2128) LRP8; APOER2; low-density lipoprotein receptor-related protein 8; LRP-8; Apolipoprotein E receptor 2	WB, IP	Human, Rat, Hamster
	ApoER2 Antibody (YA2128) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2128), targeting ApoER2, with a predicted molecular weight of 106 kDa (observed band size: 130,106 kDa). ApoER2 Antibody (YA2128) can be used for WB, IP experiment in human, rat, hamster background.

HY-P83131

	LRP2 Antibody (YA2876) low-density lipoprotein receptor-related protein 2; LRP-2; Glycoprotein 330; gp330; Megalin; LRP2; DBS	WB	Human, Mouse, Rat
	LRP2 Antibody (YA2876) is a biotin-conjugated non-conjugated IgG antibody, targeting LRP2, with a predicted molecular weight of 522 kDa (observed band size: 280 kDa). LRP2 Antibody (YA2876) can be used for WB experiment in human, mouse, rat background.

HY-P82565

	SorLA Antibody (YA2310) SORL1; C11orf32; Sortilin-related receptor; low-density lipoprotein receptor relative with 11 ligand-binding repeats; LDLR relative with 11 ligand-binding repeats; LR11; SorLA-1; Sorting protein-related receptor containing LDLR class A repe	WB, IHC-P	Human, Mouse, Rat
	SorLA Antibody (YA2310) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2310), targeting SorLA, with a predicted molecular weight of 248 kDa (observed band size: 270 kDa). SorLA Antibody (YA2310) can be used for WB, IHC-P experiment in human, mouse, rat background.

HY-P81172

	LOX 1 Antibody Lectin-type oxidized LDL receptor 1; OLR1; lectin-like low density lipoprotein receptor-1; Oxidized low-density lipoprotein receptor 1; Ox-LDL receptor 1; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; LOX-1; BLOX1; Contains: Oxidized low-density lipoprotein receptor 1, soluble form A; Oxidized low-density lipoprotein receptor 1, soluble form B; OLR1_HUMAN.	WB, IHC-P, ICC/IF, FC	Human, Rat, Rabbit
	LOX 1 Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-LOX 1 polyclonal antibody. LOX 1 Antibody can be used for: WB, IF-Cell, IHC-P, FC expriments in human, mouse background without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-W134326

Polydextrose		Fillers
Polydextrose has the effect of lowering cholesterol and plasma lipids, and can effectively reduce low-density lipoprotein cholesterol. Polydextrose significantly reduced plasma and liver cholesterol in gerbils fed with enlarged endogenous cholesterol reservoirs .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

low-density lipoprotein

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products